Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus sorafenib or lenvatinib as first-line treatment for advanced hepatocellular carcinoma
CTR20192560Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab, sorafenib, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Dec 2020; status: active.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20192560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192560.